Pneumococcal vax to be investigated prior to funding

The head of clinical research at the National Centre for Immunisation Research and Surveillance (NCIRS), Professor Robert Booy, said Pneumo­vax 23 (CSL/Merck) was a good vaccine but it was hoped Prevenar 13 would be better at preventing the majority of cases of pneumonia that occur without bacteraemia.

The manufacturer, Pfizer, confirmed it will seek NIP listing for Prevenar 13 for the over-50s, although the timing has not been decided. The indication was approved by the TGA last year and the vaccine is available on the